Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

Luana Schito, Gregg L Semenza

Research output: Contribution to journalReview article

Abstract

Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.

Original languageEnglish (US)
Pages (from-to)758-770
Number of pages13
JournalTrends in Cancer
Volume2
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Neoplasms
Immune Evasion
Neoplastic Stem Cells
Extracellular Matrix
Radiotherapy
Therapeutics
Maintenance
Hypoxia
Neoplasm Metastasis
Gene Expression
Drug Therapy

Keywords

  • oxygen biology
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hypoxia-Inducible Factors : Master Regulators of Cancer Progression. / Schito, Luana; Semenza, Gregg L.

In: Trends in Cancer, Vol. 2, No. 12, 01.12.2016, p. 758-770.

Research output: Contribution to journalReview article

@article{516708113bcd40d391b8afbbf82d1ba2,
title = "Hypoxia-Inducible Factors: Master Regulators of Cancer Progression",
abstract = "Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.",
keywords = "oxygen biology, tumor microenvironment",
author = "Luana Schito and Semenza, {Gregg L}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.trecan.2016.10.016",
language = "English (US)",
volume = "2",
pages = "758--770",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "12",

}

TY - JOUR

T1 - Hypoxia-Inducible Factors

T2 - Master Regulators of Cancer Progression

AU - Schito, Luana

AU - Semenza, Gregg L

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.

AB - Intratumoral hypoxia (reduced O2 availability) is a common finding in human cancer and leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes that contribute to angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial–mesenchymal transition, motility, invasion, metastasis, cancer stem cell maintenance, immune evasion, and resistance to chemotherapy and radiation therapy. Conventional anticancer therapies target well-oxygenated and proliferating cancer cells, whereas there are no approved therapies that target hypoxic cancer cells, despite growing clinical and experimental evidence indicating that intratumoral hypoxia is a critical microenvironmental factor driving cancer progression. In this review, our current understanding of the consequences of HIF activity and the translational potential of targeting HIFs for cancer therapy are discussed.

KW - oxygen biology

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85004065577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004065577&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2016.10.016

DO - 10.1016/j.trecan.2016.10.016

M3 - Review article

C2 - 28741521

AN - SCOPUS:85004065577

VL - 2

SP - 758

EP - 770

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 12

ER -